If you get a negative panel recommendation, ARNA should soar more than OREX
Actually I would predict that in the majority of circumstances that VVUS gets a negative panel that ARNA and OREX would go down too. The FDA is very cautious indeed about obesity drugs, and if they are very tough on one drug here they will likely follow suit on the others.